Vitamin K antagonists (VKA) are currently the most frequently used drug to prevent ischaemic stroke in atrial fibrillation (AF) patients. However, VKA use has been associated with increased vascular calcification. The aim of this study was to investigate the contribution of VKA use to coronary artery calcification in low-risk AF patients.
Introduction
Apart from other well-described clinical complications, atrial fibrillation (AF) is associated with complex thrombo-embolic mechanisms raising the risk of ischaemic stroke. 1 -4 This being the most feared complication, AF patients need intensive stroke prevention therapy. Oral vitamin K antagonists (VKA) are currently the most frequently used drug to prevent thrombo-embolic complications in AF patients with a high stroke risk. 5, 6 Recently, it has been suggested that the use of VKA is associated with enhanced tissue calcification. Experimental data suggest that VKA may decrease the activity of matrix-g-carboxyglutamic acid (Gla) protein (MGP), a strong inhibitor of soft tissue calcification. 7 -11 Rennenberg et al. 12 showed that the long-term use of VKA is associated with enhanced extra-coronary vascular calcification in patients. It is unknown whether VKA also increase calcification of the coronary arteries. Obviously, considering the clinical evidence, potential deleterious calcification by VKA is outweighed by the stroke preventive effects of VKA. However, it cannot be excluded that a subset of high-risk AF patients does develop detrimental calcification induced by chronic VKA therapy. This may also occur in a substantial number of low-risk AF patients many of whom are overtreated with VKA. 13, 14 In these patients, potential benefits of long-term stroke prevention may not weigh up to the risks of vascular calcification. We investigated the contribution of VKA use to the degree of coronary artery calcification as assessed by multislice computed tomography (MSCT) in AF patients without clinically significant cardiovascular disease.
Methods

Study population
We performed a cross-sectional observational study in 157 consecutive patients with paroxysmal AF and a low cardiovascular risk. All patients had either a cardiac multislice computed tomography (CCT) for work-up before an electrophysiological ablation of their AF (58%) or consented to undergo CCT to assess coronary artery calcification for the purpose of this study. Before CCT, patient characteristics were collected and the PROCAM risk score was determined. 15 This simple and accurate scoring scheme is widely accepted, particularly in Europe, and allows to predict the absolute 10-year risk of an acute coronary event (fatal or non-fatal myocardial infarction or acute coronary death, PROCAM risk score ,10% estimated as low risk, 10 -20% moderate risk, .20% high risk). Blood sampling was done after an overnight fast. All patients were in sinus rhythm during CCT. The study was approved by the Institutional Review Board and all patients gave written informed consent. Low cardiovascular risk was defined as a PROCAM risk score ,10%, age below 70 years, and the absence of any cardiovascular disease including significant hypertension, diabetes (fasting blood glucose ,7.0 mmol/L), or hypercholesterolaemia (total fasting cholesterol ,6.4 mmol/L). In addition, no history of coronary artery disease (CAD) (i.e. typical exercise-related angina pectoris, an exercise stress test with significant ST-segment depression if available, previous acute coronary syndrome, percutaneous or surgical coronary revascularization, or previous angiographically documented coronary disease), no significant renal dysfunction (calculated creatinine clearance .60 mL/ min, Cockcroft and Gault formula), no congestive heart failure (left ventricular ejection fraction .50%), no previous stroke, no malignancy, no thyroid disease or pulmonary disease, and no evidence for structural cardiovascular disease on echocardiogram, including the absence of left ventricular hypertrophy defined as interventricular septum and posterior wall widths ,10 mm. For the purpose of this study, we excluded all patients not fulfilling these criteria as well as patients in whom CCT was contraindicated.
Cardiac multislice computed tomography data acquisition and analysis
In all patients, a prospective non-enhanced coronary calcium scan was performed with a 64-slice MSCT scanner (Brilliance 64; Philips Healthcare, Best, The Netherlands). For quantitative assessment of coronary artery calcification, the Agatston score was calculated, using a 3 mm CT slice thickness and a detection threshold of ≥130 HU involving ≥1 mm 2 area/lesion (3 pixels). Patients were categorized as having no calcium (Agatston score ¼ 0), minimal (1 -10), mild (11 -100), moderate (101 -400), or severe (.400) coronary calcification. Cardiac CT angiography was performed using a collimation of 64 × 0.625 mm and a rotation time of 0.4 s. The tube current was 240 -400 mA (depending on body weight), at 120 kV. Contrast material (Iobitridol, Xenetix 350; Guerbet, Paris, France) at a flow rate of 7.0 mL/s was administered in the antecubital vein, with volumes depending on the total scan time (80 -110 mL). Blood pressure and heart rate were monitored before the examination. In the absence of contraindications, patients with a heart rate ≥60 b.p.m. were administered 50 -100 mg metoprolol oral or 5 -15 mg metoprolol intravenous. Bolus timing was performed by automated peak enhancement detection in the descending aorta using a threshold of 130 HU. Data analysis was performed in a consensus reading by an experienced cardiologist and a radiologist who were blinded to all medical data. Image analysis was performed on dedicated workstations for post-processing and evaluation (Cardiac Comprehensive w Analysis software, Philips Healthcare).
Echocardiography
An independent observer performed the echocardiogram while subjects were lying in the left lateral decubitus position. All patients underwent standard two-dimensional transthoracic echocardiography, including M mode, and Doppler echocardiography (Sonos 5500, Philips Medical Systems, Andover, MA, USA). Recordings were made in the standard projections (subcostal, parasternal long-axis, parasternal short-axis, four-chamber apical long-axis, and two-chamber apical long-axis views). Aortic diameter, atrial volumes, ventricular wall thickness, left ventricular dimensions, left ventricular mass, left ventricular ejection fraction, caval vein width and collapse index, valve disorders, wall motion disorders, and Doppler flow patterns of the mitral valve (E-wave, A-wave) were determined in all patients according to the recommendations of the American Society of Echocardiography. 16 
Statistical analysis
Continuous variables are expressed as mean and standard deviation; categorical variables are expressed as absolute numbers and percentages.
Baseline variables were compared with an independent t-test (twotailed) after performing Levene's test for equality of variances in all normally distributed continuous variables and the Mann-Whitney test (two-tailed) in all not normally distributed variables. Categorical variables were tested with two-sided Fisher's exact test. Spearman's rank correlation coefficient was used for testing correlation between the mean Agatston score and the duration of VKA use.
All parameters showing a significant univariate relation with an increased coronary Agatston score and those representing a plausible mechanism in terms of calcification 17, 18 [age, VKA duration, left atrium (LA) diameter, posterior wall width, statins, angiotensin-converting enzyme (ACE)-inhibitors] were included as covariates in a logistic regression model (retention level set at 0.1), odds ratios and 95% confidence intervals (CIs) were calculated, and results were checked for interaction (of note, aspirin was not included in the model since it naturally mirrors VKA use in patients with AF). The final selected model included the following patient variables: age and VKA duration. The discriminatory power of the final logistic regression model was measured by the area under the ROC curve. Since patients were not randomly assigned to the use of VKA, we adjusted for factors favouring VKA prescription using the propensity score in order to reduce the selection bias. We entered all confounders showing a significant univariate relation with prescription of VKA [sex, body mass index (BMI), rhythm control, LA diameter] as covariates in a binary regression model in order to estimate the propensity score for each patient. 19 This score reflected the probability that a patient would receive VKA. After fitting the model, we ranked all patients by their estimated propensity score and grouped patients within quintiles of equal size based on the estimated propensity score. We calculated the hazard ratio (HR) and 95% CI for coronary calcium score comparing within each quintile patients who received VKA treatment and those who did not. The area under the ROC curve was used to assess the discriminatory ability of the model and we examined the model calibration using the Hosmer -Lemeshow goodness-of-fit test.
Statistical analysis was performed with SPSS statistical software (SPSS, Inc. release 18.0) and statistical significance was assumed for P , 0.05.
Results
Baseline characteristics are shown in Table 1 . Out of the total of 157 patients, 79 (50%) had an increased coronary artery calcium score. The other 78 patients did not have any detectable calcium in the coronary vessels. Patients with increased Agatston score were older than those with Agatston ¼ 0 (60 + 7 vs. 54 + 9 years, P , 0.001). Out of the total of 157 patients, 71 (45%) were chronic VKA users, although their CHA 2 DS 2 -VASc score was 0 (n ¼ 55) or 1 (n ¼ 16, because of female sex category). 20 The other 86 patients were not on VKA and had not used anticoagulants before. There were significantly more VKA users among patients with increased Agatston score than in those with Agatston score ¼ 0 (58 vs. 32%, P ¼ 0.001). The duration of VKA treatment varied between 6 and 143 months (mean 46 months). In line with the low cardiovascular risk of this population, no differences in clinical characteristics were found between patients on VKA treatment and non-anticoagulated patients ( Use of VKA and coronary calcification in AF both groups, atria in the VKA treatment group were significantly larger, most likely because of longer AF history. A total of 25 (35%) patients using VKA had a coronary artery calcium score of zero compared with 53 (62%) patients in the nonanticoagulated group (P ¼ 0.001). Median coronary artery calcium scores differed significantly between patients without and patients with VKA treatment [0, inter-quartile range (IQR) 0 -40, vs. 29, IQR 0-184; P ¼ 0.001]. Out of a total of 2512 coronary artery segments, 37 (1.5%) were excluded because of impaired image quality. The total number of segments containing focal calcified lesions was 43 (3.2%) in patients not using VKA vs. 94 (8.4%) in those using VKA (P , 0.001). The total amount of coronary artery segments containing a mixed plaque (plaque composed of a mixture of soft plaque and calcification) was not significantly different between the non-anticoagulated and the anticoagulated groups (3.3 vs. 3.5%, P ¼ 0.567). Mean Agatston scores increased significantly with the duration of VKA use (no VKA: 53 + 115, 6 -60 months on VKA: 90 + 167, and .60 months on VKA: 236 + 278; r ¼ 0.453, P , 0.001). Figure 1 shows the dispersion of different Agatston score categories in patients with different duration of VKA use according to different age groups.
Multivariable logistic regression analysis revealed that age and VKA treatment duration (months) were significantly related to increased coronary calcium score ( Table 3 ). This final model had a good discriminative power with a c-statistic of 0.8. Of note, including VKA duration as a categorical variable (no VKA, 6-60 months, and .60 months) or binominal variable (VKA use yes/ no) to the model did not change the results. Repeating this analysis after addition of the propensity score as a continuous variable did not change the effects of VKA treatment on the coronary calcium score. The propensity score model had a good discriminatory ability (c-statistic ¼ 0.7) and the Hosmer-Lemeshow test for goodness-of-fit was not statistically significant (P ¼ 0.916), which is in accordance with a good calibration.
After matching patients according to propensity score quintiles (Q1: ,0.32388, Q2: 0.32389-0.40409, Q3: 0.40410-0.50302, Q4: 0.50303-0.57883, and Q5: .0.57883), the use of VKA was associated with increased Agatston score in Quintile 2 (15 vs. 70%, HR ¼ 13.222, 95% CI 2.129 -82.129, P ¼ 0.006) and Quintile 5 (50 vs. 84%, HR 5.333, 95% CI 1.000-28.435, P ¼ 0.050; Table 4 ). In the other quintiles, a non-significant trend of increased Agatston score was observed in patients using VKA (Figure 2) .
In comparison with the other subgroups, patients with the most likelihood of receiving VKA (Quintile 5) were more often male, more often used anti-arrhythmic drugs, were more likely to have higher body mass index (BMI), and had larger atrial size ( 
Discussion
This is the first study showing that AF patients using VKA despite a low vascular risk show increased levels of coronary calcification. Mean coronary artery calcium scores were highest in patients with longest VKA use and logistic regression analysis indicated VKA use, together with age as independently related to increased coronary calcium score. These results suggest that the chronic use of VKA may enhance potentially harmful coronary calcification in a subset of low-risk AF patients.
Vitamin K antagonists and arterial calcification
Vitamin K is an essential micronutrient that serves as a cofactor for the transformation of selective glutamic acid residues into Gla during the biosynthesis of the so-called Gla proteins. 21 Matrix-Gla protein, a vitamin K-dependent protein, is produced by vascular smooth muscle cells (VSMCs) and chondrocytes. 21 Matrix-Gla protein is one of the strongest inhibitors of soft tissue calcification due to an effect on bone morphogenetic protein type 2 and binding of mineral and mineral ions in the matrix. 7 It has been demonstrated that MGP-deficient mice develop extensive medial calcification of the arteries. 9 In animal studies, the use of warfarin, a VKA derivative, induced inactive MGP and subsequent vascular calcification. 10 Circulating MGP levels are inversely correlated with the severity of coronary artery calcium as assessed by electron-beam CT. 8, 9 Recently, Koos et al. 22 suggested that longterm VKA treatment may decrease circulating MGP levels leading to increased aortic valve calcifications. The excess coronary calcification as seen in our study might be mediated through inhibition of MGP carboxylation by VKA.
The role of calcification in coronary artery disease
Pathomorphologically, there are at least two distinct forms of vascular calcification. Intima calcification of the coronary arteries (atherosclerosis) is an active process and can be seen in more advanced stages of atherosclerotic plaque development. 23, 24 It occurs only at sites of atherosclerotic plaques, where there is already a combination of cellular necrosis, inflammation, and cholesterol deposition, and is more frequent in advanced lesions and in the elderly. 25, 26 Calcification of the media (arteriosclerosis), also known as Mö nckeberg's sclerosis, can occur independently of atherosclerosis and is almost exclusively associated with VSMCs. 27 It is particularly common in the setting of metabolic disorders such Use of VKA and coronary calcification in AF as diabetes mellitus and chronic kidney disease. Besides, it is shown that MGP expression is lower in the media of arteries of patients with Mö nckeberg's sclerosis than in normal vessels. 28 Cardiac CT is unable to directly distinguish between medial and intimal calcification, as the minimal voxel size for 64-slice scanners has been reported as 0.4 mm 3 (using dedicated acquisition techniques, e.g.
z-flying focal spot). 29 In this study, we showed that focal calcifications were significantly more prevalent in the VKA treatment group, which could be an expression of inactive MGP-induced medial calcification. Irrespective of the above, it must be noted that calcification, independent from a mixed or focal pattern, is a well-established cardiovascular risk factor. Apart from age, we revealed an independent relation between coronary artery calcification and VKA. This implicates that the use of VKA in low-risk AF patients accelerates the process of calcification and atherosclerosis in patients with heretofore unknown CAD.
The exact contribution of coronary artery calcification to the stability of atherosclerotic plaques is not clearly defined. Some studies describe that plaque calcification initially destabilizes a plaque by providing areas of interface between high-and lowdensity where a plaque is more prone to rupture. 30 Plaques may also rupture because of physical stress exerted by calcified nodules. 31, 32 However, calcification may also represent beneficial scaffolding which could be seen as protective by strengthening atherosclerotic plaque prone to rupture. But still then enhancing the process of calcification by VKA may promote vasomotor dysfunction in the coronary arterial tree. Multislice computed tomography is a non-invasive technique that can easily detect CAD at its earliest stages reflected by the presence and severity of coronary artery calcification. 33, 34 The coronary artery calcium score is an important marker which is used to identify a high-risk group of asymptomatic patients who have clinically important silent ischaemia. 35 Even a low coronary artery calcium score could provide information about the vascular status of a patient. Minor lesions in the main coronary arteries could be a sign of advanced vascular disease in the microvasculature which may lead to important ischaemia, possibly even influencing the AF substrate. A recent meta-analysis among 30 prospective studies revealed that the presence of calcifications is associated with a three-to four-fold higher risk for mortality and cardiovascular events.
36,37
Low-risk atrial fibrillation and the use of vitamin K antagonists
Vitamin K antagonists are among the most widely used drugs to prevent stroke in AF. However, the long-term effects on coronary artery calcifications have not been studied in detail. Atrial fibrillation is often associated with vascular disease; in particular, hypertension, CAD, and diabetes mellitus. A large population-based study recently showed that there is a high prevalence of AF among patients with, or at high risk of, atherosclerosis. 38 The same study found that AF in patients with CAD was associated with a major increase in cardiovascular mortality and morbidity. Even in lone AF, vascular complications have been described in 50% of the patients during long-term follow-up. 39 Besides, atrial myocardial perfusion abnormalities are common in patients with lone recurrent AF. 40 These data suggest that a significant proportion of low-risk AF patients is susceptible to vascular disease and that every effort should be taken to avoid and control risk factors. Considering the findings of our study and the fact that many low-risk AF patients are overtreated with VKA in clinical practice, 13 future studies need to clarify the risks VKA treatment represents in terms of coronary calcification. Until then overtreatment should be avoided, especially in the young low-risk AF patient whom faces a lifelong career as a VKA user. In this respect, new anticoagulants such as dabigatran and rivaroxaban may form a welcome alternative.
41,42
Study limitations
This study has several limitations that should be reported. At first, this is a cross-sectional analysis. A cause and effect relationship could therefore not be investigated. Secondly, vitamin D and parathyroid hormone (PTH) homeostasis and serum MGP were not studied but could have added to understanding biological pathways leading to VKA-induced calcification. On the other hand, it is likely that vitamin D or PTH homeostasis in this low-risk population with normal renal function would probably be normal or near normal and therefore would not change the results significantly. Thirdly, no follow-up data are available at this point. However, the strength of our study is that we selected low-risk AF patients to reduce the impact of associated vascular disease usually seen in high-risk patients, thereby enhancing identification of potentially deleterious effects of VKA. In previous studies, patients with advanced disease were studied focusing on valve and vessel wall. 8, 43 However,
showing an independent effect of VKA may be impossible in these patients because of other calcification processes related to their vascular or valvular disease. This was a small non-randomized study. While the findings are potentially very important, the results should not be overstated. Although we optimally tried to take into account the selection bias for those who did vs. those who did not receive VKA by means of multivariable modelling and propensity score analysis, both techniques cannot account for unknown or unmeasured potential confounding factors. Moreover, the effect of VKA on coronary calcification was not entirely comparable within propensity score quintiles. We have no clear explanation for these imbalances other than the low patient number per quintile. Nevertheless, we would like to emphasize that three out of five quintiles show a clear difference regarding increased Agatston score in VKA users and there is a trend towards the same finding in the other two quintiles. In addition, one should also bear in mind that all these patients actually had no strict indication for oral anticoagulation since they had low-risk AF.
A long-term large-scale randomized study may corroborate our results even in high-risk patients, in particular by comparing VKA to one of the new oral anticoagulants.
Conclusion
Patients using VKA despite a low risk of cardiovascular events show increased levels of coronary calcification as detected by CT angiography. A long-term large-scale randomized study is needed to corroborate the current observations.
